
Adherex Technologies Inc. (NASDAQ:FENC – Free Report) – Research analysts at HC Wainwright upped their Q3 2027 earnings per share estimates for Adherex Technologies in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.28 per share for the quarter, up from their previous estimate of $0.25. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2027 earnings at $0.33 EPS.
Adherex Technologies (NASDAQ:FENC – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. Adherex Technologies had a return on equity of 8.96% and a net margin of 2.52%. The business had revenue of $19.61 million for the quarter, compared to analysts’ expectations of $18.87 million.
Several other equities research analysts have also recently weighed in on the company. Zacks Research upgraded Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 12th. Wedbush boosted their price objective on shares of Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. B. Riley Financial reaffirmed a “buy” rating and set a $19.00 price objective (up from $18.00) on shares of Adherex Technologies in a research note on Monday. Finally, Weiss Ratings raised shares of Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Adherex Technologies has a consensus rating of “Buy” and a consensus price target of $17.50.
Read Our Latest Analysis on FENC
Adherex Technologies Stock Down 1.8%
FENC stock opened at $13.33 on Thursday. The firm has a market capitalization of $469.48 million, a PE ratio of 194.00 and a beta of 1.29. Adherex Technologies has a twelve month low of $5.65 and a twelve month high of $13.85. The stock has a 50-day simple moving average of $10.71 and a two-hundred day simple moving average of $9.45.
Insider Transactions at Adherex Technologies
In other news, CFO Robert Andrade sold 75,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total transaction of $883,500.00. Following the completion of the transaction, the chief financial officer owned 217,675 shares of the company’s stock, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. This trade represents a 55.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 10.73% of the company’s stock.
Adherex Technologies Company Profile
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Recommended Stories
- Five stocks we like better than Adherex Technologies
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
